Arrowhead Pharmaceuticals (NASDAQ:ARWR) Rating Lowered to "Hold" at Wall Street Zen

Wall Street Zen lowered shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR - Free Report) from a buy rating to a hold rating in a research note issued to investors on Friday morning.

A number of other research analysts have also commented on ARWR. HC Wainwright reaffirmed a "buy" rating and set a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, May 20th. Chardan Capital reissued a "buy" rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, May 13th. Finally, Citigroup decreased their price target on shares of Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating for the company in a research note on Tuesday, May 13th. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $43.71.

Arrowhead Pharmaceuticals Price Performance

Shares of ARWR traded down $2.09 during mid-day trading on Friday, reaching $16.76. 3,012,546 shares of the stock traded hands, compared to its average volume of 1,580,857. The firm has a fifty day moving average price of $16.34 and a 200 day moving average price of $16.32. The company has a market cap of $2.31 billion, a price-to-earnings ratio of -11.97, a price-to-earnings-growth ratio of 19.71 and a beta of 0.93. The company has a current ratio of 5.15, a quick ratio of 5.15 and a debt-to-equity ratio of 0.31. Arrowhead Pharmaceuticals has a 1 year low of $9.57 and a 1 year high of $29.86.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last announced its earnings results on Monday, May 12th. The biotechnology company reported $2.75 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $2.81. The company had revenue of $542.71 million during the quarter, compared to analysts' expectations of $116.27 million. During the same quarter last year, the firm posted ($1.02) earnings per share. As a group, equities research analysts predict that Arrowhead Pharmaceuticals will post -2.42 earnings per share for the current year.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC boosted its stake in shares of Arrowhead Pharmaceuticals by 297.6% during the 1st quarter. GAMMA Investing LLC now owns 2,175 shares of the biotechnology company's stock worth $28,000 after acquiring an additional 1,628 shares during the last quarter. GF Fund Management CO. LTD. purchased a new position in shares of Arrowhead Pharmaceuticals during the 4th quarter worth $49,000. CWM LLC boosted its stake in shares of Arrowhead Pharmaceuticals by 134.3% during the 1st quarter. CWM LLC now owns 4,401 shares of the biotechnology company's stock worth $56,000 after acquiring an additional 2,523 shares during the last quarter. KBC Group NV boosted its stake in shares of Arrowhead Pharmaceuticals by 40.8% during the 1st quarter. KBC Group NV now owns 7,356 shares of the biotechnology company's stock worth $94,000 after acquiring an additional 2,132 shares during the last quarter. Finally, XTX Topco Ltd purchased a new position in shares of Arrowhead Pharmaceuticals during the 1st quarter worth $133,000. Institutional investors own 62.61% of the company's stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.